News and Comments

Exelixis: Results Demonstrate the Potential of Cabozantinib to Become the Gold Standard First Line Treatment for Advanced RCC

  Monday, May 23, 2016

Yes, indeed, the good news has come from the randomized CABOSUN phase 2 trial with Exelixis’ (EXEL) drug cabozantinib. The news is indirectly telling us that Cabozantinib may soon become the first-line treatment for previously untreated advanced renal cell carcinoma (RCC).  More...

Biogen: A Fruitful Collaboration in Gene Therapy. A Small Gene Therapy Firm That You Should Know

  Tuesday, May 17, 2016

COLLABORATIONS  More...

Seres Therapeutics Collaborates with Memorial Sloan Kettering Cancer Center to Improve Immunotherapy

  Friday, May 13, 2016

Seres Therapeutics (MCRB), is microbiome therapeutics platform company. It focuses on developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome, where the natural state of bacterial diversity and function is imbalanced.  More...

Exelixis Again. The Road to Defeating DMD. Two New Important IPOs

  Monday, May 09, 2016

EXELIXIS AGAIN More...

A Judge is Offended About False Claims Against Gilead. Good News from Regeneron

  Monday, May 02, 2016

GILEAD SCIENCES More...

The FDA Approval of Exelixis Drug Cabometyx™ Is Indeed Great News

  Tuesday, April 26, 2016

Congratulation.   More...

Nectar Therapeutics and Seattle Genetics at the AACR Meeting

  Tuesday, April 19, 2016

Meaningful Presentations  More...

Good News from Juno Therapeutics and from Abbvie. Disappointing News for Clovis Oncology

  Wednesday, April 13, 2016

Juno Therapeutics (JUNO) is due to receive a fee payment of $50 million from Celgene. The reason for this compensation is that Celgene has exercised its option to develop and commercialize Juno CD19 program outside North America and China.  More...

Theravance Biopharma Drug Vibativ Overcomes Serious Infections. See Also Juno Therapeutics In China

  Monday, April 11, 2016

Dealing With Bacterial Resistance To Antibiotics    More...

Human Longevity Firm Aims at Bringing the Missing Full Picture of Human Health

  Thursday, April 07, 2016

  More...


Recent Postings


Archive


Tags

Alnylam (ALNY) BIOMARIN (BMRN) Micromet (MITI) Abbott Laboratories (ABT) Roche (RHHBY) Rapamune Pluristem (PSTI) C4 Therapeutics Human Genome Sciences (HGSI) Intercept (ICPT) GlaxoSmithKline (GSK) Vertex (VRTX) Theravance (THRX) TOKAI (TKAOI) Amgen (AMGN) Jazz Pharmaceuticals (JAZZ) Intermune (ITMN) Auspex (ASPX) Anacor (ANAC) Dynavax (DVAX) ARCA (ABIO) galapagos (GLPG) Inovio (INO) Benlysta (belimumab) Elan (ELN) Xoma (XOMA) Vitae Pharmaceuticals (VTAE) HALOZYME (HALO) ADVENTRIX (ANX) Genentech Sanofi (SNY) REGULUS (RGLS) Ariad (ARIA) KITE (KITE) Intrexon (XON) Dendreon (DNDN) SYNTA (SNTA) Onyx (ONXX) ACADIA (ACAD) Sanofi (SNA) Roche (ROCHE) JUNO (JUNO) RenenxBio (RGNX) NANTKWEST (NK) Array Pharmaceuticals (ARRY) Mirati Therapeutics (MRTX) Sarepta (SRPT) ISIS (ISIS) Gilead (GILD) Galena (GALE) VANDA (VNDA) KERYX (KERX) Theravance Bio Pharma (TBPH) NEKTAR (NKTR)) Incyte (INCY) OSI (OSIP) Zerenex Anadys (ANDS) Agenus (AGEN Agenus (AGEN) Sanofi-Aventis (SAN) Ziofpharm (ZIOP) Prolor Biotech (PBTH) Biocryst (BCRX) Multiple Myeloma Sequenom (SQNM) SERES THERAPEUTICS (MCRB) Biogen Idec (BIIB) ABBVIE (ABBV) Merck (MRK) PTC Therapeutics (PTCT) Velcade (bortezomib) Telaprevir Illumina (ILMN) Human Longevity (HLI) Prosensa (RNA) Editas (EDIT) ImmunoGen (IMGN) ZALTRAP™ Revlimid (lenolidamide) Trastuzumab-DM1 Regeneron (REGN) Ridaforolimus Sangamo (SGMO) Alder Biopharmaceuticals (ALDR) Bristol-Myers Squibb (BMY) CompuGen (CGEN) Ionis (IONS) IDERA (IDRA) Valeant Pharmaceuticals International (VRX) Herceptin AERIE PHARMACEUTICALS Endometrial Cancer Cytokinetics (CYTK) SUNESIS PHARMACEUTICALS (SNSS) Tysabri Seattle Genetics (SGEN) Aimmune Therapeutics (AIMT) Exelixis (EXEL) GUARDIAN HEALTH Idenix (IDIX)